As anticipated, the 15-month anti-TNF-α treatment conducted in this study proved to be effective with respect the RA patients, significantly reducing DAS28-ESR and the levels of all inflammation biomarkers, namely, ESR, CRP, and MMP-3. The gene discussed is CRP; the disease is rheumatoid arthritis.